O2h and Hypoxium Announce an Agreement to Offer Hypoxium's Specialised In Vitro, Cell-Based Oncology Assays via O2h's Biology Affiliate Program
CAMBRIDGE, England, June 25 /PRNewswire/ -- O2h has initiated a networked
approach towards being a full service discovery services company at the
forefront of drug discovery research. O2h has established a new biology lab
on-site in Ahmedabad, India offering physio-chemical and CYP450 assays. ...
Quark Pharmaceuticals Presented At ARVO Data Showing That PF-04523655 Enters Retinal Cells And Elicits Its Pharmacologic Effect Via Target Gene Knock-Down Without Activating TLR3
FREMONT, Calif., May 11 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company discovering and developing novel RNA interference (RNAi)-based therapeutics, today announced that Elena Feinstein, M.D., Ph.D., Chief Scientific Officer, presented a study titled, "PF-04...
IntraLinks Poll: Half of Clinical Trial Management Professionals Share Critical Information Via E-Mail
NEW YORK, Jan. 26 /PRNewswire/ -- Fifty percent of clinical trial management professionals in the life sciences industry still share high-value, proprietary company information via
e-mail, while others do so via
fax (15 percent) or overnight courier (14 percent), according to a recent IntraLinks(...
Prominent Physician Achieves Success Using Topical Sinus Medications via Pulsitile Irrigation
Murray Grossan, MD (creator of the Hydro-Pulse sinus irrigation device) describes his successful treatment protocol for applying antibiotics, anti-fungals and anti-inflammatories directly into the sinus cavities using a pulsating irrigation device. This treatment has been extremely helpful for hi...
American Oriental Bioengineering Announces Proposed Private Offering to Raise $125 Million via Convertible Preferred Stock
NEW YORK, June 3 /PRNewswire-FirstCall/ -- American Oriental
Bioengineering (NYSE: AOB ) today announced that it plans to make a private
offer, subject to market conditions and other factors, to sell
approximately $125 million in aggregate liquidation preference of newly
issued convertible pr...
Researchers develop method for transmitting medical images via cell phones
Jerusalem, April 29, 2008 A process to transmit medical images via
cellular phones that has been developed by a Hebrew University of Jerusalem researcher has the potential to provide sophisticated radiological diagnoses and treatment to the majority of the worlds population lacking access to su...
Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
MUNICH, Germany, March 10 /PRNewswire-FirstCall/ -- Halozyme
Therapeutics, Inc. (Nasdaq: HALO ), a biopharmaceutical company developing
and commercializing products based on the extracellular matrix, today
announced new safety and pharmacokinetic data from a second generation
ESBATech's Antibody Fragments Demonstrate Penetration into the Eye with Topical Delivery via Eye Drops
Preclinical results to be presented at two international scientific meetings
ZURICH, Switzerland, Feb. 25 /PRNewswire/ -- ESBATech AG, a leading
developer of antibody fragment therapeutics, today announced that it has
achieved high concentrations of its antibod...
Green County courts to hold hearings via video conferencing
Green County will soon use video conferencing to keep down costs by allowing people to make initial appearances in court from jail or elsewhere without being transported, according to The Times of Monroe
A 2003 study by the Wisconsin Office of Justice Assistance found the county could save $...
Fighting spam via blue frogs
Some companies just can't wait for DEMOfall, and one of those is Blue Security , which launched the public beta of its Blue Frog "Do Not Intrude Registry" early last week.
The concept is like the national Do Not Call list that has deterred telemarketers from ruining your dinner. Instead of th...
Ca++-Induced G Protein Coupled Receptor (GPCR) Activation Monitored via Aequorin Luminescence in the LMax Microplate Luminometer (MaxLine Application Note #42)
Jinfang Liao, M.D., Ph.D. and Evelyn McGown, Ph.D.
Molecular Devices Corporation, 8/00
The photoprotein aequorin, a bioluminescent protein from the coelentratejellyfish Aequorea victorea, has proven to be highly sensitive to the trace amou...
...loidal platinum nanocrystals in solution with subnanometer resolution. Their results showed that while some crystals in solution grow steadily in size via
classical nucleation and aggregation meaning monomer molecules collide and join together others grow in fits and spurts, driven by "coalescence even...
Volcano Corporation Presentation At Canaccord Adams Conference To Be Webcast
...c Daylight Time).
The presentation will be available through the conference website at http://www.wsw.com/webcast/cana c cord/volc/ and via
the company's website at ww w .volcanocorp.com .
Volcano Corporation (NASDAQ: VOLC ) offers a broad suite of devices designed to facilit...
Novavax Reports Second Quarter 2009 Financial Results
...gement will host its quarterly conference call at 10:00 a.m. Eastern time (7:00 a.m. Pacific time) today. The live conference call will be accessible via
Novavax's website at www.nov a vax.c o m under Investor/Events or by telephone at 1 (866) 206-5917 (U.S. or Canada) or 1 (703) 639-1106 (Inter...
EGEN, Inc. Announces the Promotion of Jason Fewell, Ph.D., to Vice-President of Preclinical Research and Development
... privately held biopharmaceutical company located in Huntsville, Alabama and is focused on developing therapeutics for the treatment of human diseases via
nucleic acid (DNA and RNAi) delivery. The Company has a significant intellectual property position in delivery systems, their novel compositions with...
InterMune Reports Second Quarter 2009 Financial Results and Business Highlights
...sed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via
InterMune's web site at www.intermune.com .
Actimmune(R) is a registered trademark of InterMune, Inc. Pegasys(R) and Copegus(R) are registere...
SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights
...s study showed that as many as 15% of women in the study group determined to be negative for the presence of human papillomavirus (HPV) in the cervix, via
the most commonly used test for HPV DNA, may actually be infected with the virus at clinically relevant viral loads. The company is exploring various ...
OncoGenex Reports Second Quarter 2009 Financial Results
further clinical investigation.
- The Company reached an agreement with the U.S. Food and Drug
Administration (FDA) via
the special protocol assessment process (SPA)
on an amendment to the design of a phase 3 registration trial of
OGX-011. The FDA has agre...
Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody
...or of Notch signaling, which is a pathway known to be important in stem cells and cancer. Blocking DLL4 results in broad-spectrum anti-tumor activity via
multiple mechanisms, including disrupting angiogenesis, inhibiting cancer stem cell growth and promoting cell differentiation. OMP-21M18 is currently...
Webcast Alert: Transgenomic Inc. Announces Second Quarter 2009 Earnings Release Conference Call Webcast
...ontact: Investor Relations, 402-452-5400
To access the call via
telephone, call 800-894-5910 or 785-424-1052. A replay of the call will be available via
telephone until 11:59 pm ET on Wednesday, August 26, 2009. To access, dial...
Repligen Reports First Quarter Fiscal Year 2010 Financial Results
Repligen will host a conference call and webcast on Thursday, August 6th at 10:00 a.m. EDT, to review financial results. This call can be accessed via
Repligen's website at www.repligen.com or by calling (800) 638-4930 for domestic calls and (617) 614-3944 for international calls. Participan...
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
...r this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 4035217.
An audio webcast can also be accessed via
the investor section of the Amicus Therapeutics Web site at www.amicustherapeutics.com under Investors: Events and Presentations. Web participants...
Pharmasset to Present at Canaccord Adams Conference
...will provide an overview of the company on Wednesday, August 12, 2009 at 9:00 AM (ET).
To access a simultaneous webcast of Mr. Price's overview via
the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/e...
AIAG and MichBio Form New Collaborative Partnership
...n 25 years, OEMs, suppliers, service providers, government and academia have worked collaboratively to drive cost and complexity from the supply chain via
global standards development and harmonized business practices. AIAG membership has grown to include preeminent OEMs such as Caterpillar, Chrysler LL...
Ceregene Receives Additional Grant From Michael J. Fox Foundation to Expand Long-Term Testing of CERE-120 Patients
...tes, with two thirds of patients receiving CERE-120 and one third enrolled into a control group. Patients received a single administration of CERE-120 via
stereotactic neurosurgery to deliver the drug into the putamen region of the brain and were followed for a minimum of 12 months for safety and efficac...
AEterna Zentaris to Announce Second Quarter 2009 Financial and Operating Results on August 11, 2009
...ost a conference call and webcast to discuss these results later that same day at 10:00 a.m., Eastern Time.
Participants may access the live webcast via
the Company's website at www.aezsinc.com in the "Investors" section, or by telephone using the following numbers: 800-588-4942, 416-644-3426, or 514...
NxStage Reports Second Quarter 2009 Financial Results
...sscode is 18840646. The call will also be webcast LIVE and can be accessed via
the investor relations section of the Company's website at www.nxstage.co...asscode 52867664. An online archive of the conference call can be accessed via
the investor relations section of the Company's website at www.nxstage.co...
Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress
...ronic regions of genes.
Conference Call Details
To access the live conference call today, August 4, at 4:30 p.m. Eastern Time via
phone, please dial (877) 361-8830 from the United States and Canada or +1(706) 679-8297 internationally. The conference ID is 22377396. Please dial ...
Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist
Oramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines presently delivered via
Oramed is seeking to revolutionize the treatment of diabetes through its
patented flagship product, an orally ingestible insulin capsule cu...
Bionovo, Inc. to Announce Second Quarter Fiscal Year 2009 Financial Results on Monday, August 10, 2009
... access the call by dialing (800) 860-2442 or (412) 858-4600, or can listen via
a live Internet web cast, which can be found at http://bionovo.com/investors/events . A replay of the call is available via
web cast at http://bionovo.com/investors/events for 30 days or by pla...
Human Genome Sciences Announces Closing of Public Offering
... please visit the Company's web site at www.hgsi.com . Health professionals and patients interested in clinical trials of HGS products may inquire via
e-mail to firstname.lastname@example.org " target="_new"> email@example.com or by calling HGS at (877) 822-8472.
HGS, Human Genome Sciences, ABthrax, Alb...
Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia
...n to developing Restanza as a potential treatment for CAP, Advanced Life Sciences has received a $3.8 million contract from the Department of Defense, via
the Defense Threat Reduction Agency (DTRA), to fund NDA-enabling studies to evaluate Restanza's efficacy against bioterror agents such as tularemia, p...
Nektar Therapeutics to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference in New York City
...e at the Millennium Broadway Hotel in New York City on Wednesday, August 5, 2009 at 1:45 p.m. Eastern time.
The presentation will be accessible via
a Webcast through a link posted on the Investor Relations, Events Calendar section of the Nektar website: http://www.nektar.com . This Webcast wi...
Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients
...atment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via
the Toll-like receptor 7, or TLR7, pathway in hepatitis C.
Safe Harbor Statement
Statements in this press release that are not strict...
Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights
... ANA773 is the Company's oral inducer of endogenous interferons that acts via
the toll like receptor 7 (TLR7) pathway.
Phase I Clinical Trial in...ANA773, an oral, small-molecule inducer of endogenous interferons that acts via
the Toll-like receptor 7, or TLR7, pathway in hepatitis C.
Transave Enters Into Cooperative Research Agreement With NIH To Study ARIKACE(TM) In Nontuberculous Mycobacteria
...hly efficient aerosolization of medication including liposomal formulations via
a vibrating, perforated membrane that includes thousands of laser drilled h...s. The company's major focus is on developing antibiotic therapy delivered via
proprietary advanced pulmonary liposome technology in areas of high unmet...
Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results
This call is being webcast by Thomson/CCBN and can be accessed via
Repligen's website at www.repligen.com . If you are unable to access the webcast via
the internet, you may also listen to the live broadcast by calling (800) 6...
PDI, Inc. to Hold Second Quarter 2009 Financial Results Conference Call on Wednesday, August 5, 2009
... from the U.S. and Canada, or for international callers, please dial (706) 643-1203.
Those interested in listening to the conference call live via
the Internet may do so by visiting the Investor Relations section of PDI's web site at http://www.pdi-inc.com . A replay will be available on the...
Sangamo BioSciences Reports Second Quarter 2009 Financial Results
...host a conference call today, July 29, 2009 at 5:00 p.m. ET, which will be open to the public. The call will also be webcast live and can be accessed via
a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" http://investor.sangamo.com/events.cfm...
Neurocrine Biosciences Reports Second Quarter 2009 Results
...tional) using the conference passcode 7NEURO. The call can also be accessed via
the webcast through the Company's website at http://www.neurocrine.com ...Biosciences, Inc. news releases are available through the Company's website via
the internet at http://www.neurocrine.com
In addition to hist...